Stan Fisher is a first-chair trial lawyer and counselor who focuses his practice primarily on issues that affect technology companies.  Stan has tried numerous cases involving patent, FDA, and antitrust issues, as well as matters involving contracts, licensing, and business torts. 

Stan has been consistently ranked as an “IP Star” by Managing Intellectual Property (2021-2024); and LMG Life Sciences Guide recognized him as a “Leading Life Science Star” since 2021.  In 2022, LMG Life Sciences identified Stan among the finalists for the “General Patent Litigator of the Year (DC Metro)” award, and in 2023 and 2024, he was a recognized as a finalist for “Hatch-Waxman Litigator of the Year (Branded)." IAM Patent 1000 has highlighted Stan as a “Leading Patent Litigation Attorney” in its guide since 2020.  The 2020 publication noted Stan has “broad horizons as a trial lawyer and litigates with confidence and poise in diverse technical fields, across all areas of intellectual property and in regulatory, antitrust and contract disputes” and the 2022 edition emphasizes Stan’s standing as a “leading trial lawyer.” Both in September 2022 and May 2021, The American Lawyer recognized Stan as a “Litigator of the Week Runner Up” for successfully representing Merck in a major trial victory and IPR proceedings, respectively, concerning patents covering the blockbuster sitagliptin products: Januvia, Janumet, and Janumet XR.

In addition to Stan’s patent practice, he serves as Co-Chair of the firm’s Food and Drug Administration practice group. In this space, he focuses specifically on the intersection of FDA law, patent law, and antitrust law, advises on issues with the Orange Book, regulatory exclusivities, and other issues that are adjunct to pharmaceutical and biotech patent litigation. Stan’s experience litigating matters involving the FDA has been highlighted by IAM Patent 1000 with the publication describing Stan as a “top” FDA lawyer. The 2021 edition highlighted Stan's "vast biopharmaceutical experience” and explained that he “makes full use of his finely honed advocacy skills and intuitive understanding of Food and Drug Administration regulatory requirements and antitrust law."  He also has an active practice litigating trade secrets, trademarks, and copyrights.   

Stan serves as Professorial Lecturer in Law at The George Washington University Law School, where he teaches Chemical & Biotech Patent Law, a course Stan recently re-designed to focus on patent, regulatory, and antitrust issues arising in Hatch-Waxman, BPCIA, and other pharmaceutical and biotechnology patent matters.